Clinical Trial: A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transver
Brief Summary: The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.
Detailed Summary:
Sponsor: RXi Pharmaceuticals, Corp.
Current Primary Outcome: Reduction in recurrence of hypertrophic scarring after scar revision surgery [ Time Frame: 9 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Safety of RXI-109 [ Time Frame: 9 months ]
Original Secondary Outcome: Same as current
Information By: RXi Pharmaceuticals, Corp.
Dates:
Date Received: January 6, 2014
Date Started: November 2013
Date Completion:
Last Updated: June 20, 2016
Last Verified: June 2016